Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Autor: Iqbal M; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida. Electronic address: Iqbal.madiha@mayo.edu., Kumar A; Department of Internal Medicine, Research Methodology and Biostatistics Core, Office of Research, University of South Florida Morsani College of Medicine, Tampa, Florida., Dreger P; Department of Medicine V, University of Heidelberg, Heidelberg, Germany., Chavez J; Moffitt Cancer Center, Tampa, Florida., Sauter CS; Division of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio., Sureda AM; Department of Hematology, Institut Català d'Oncologia (ICO), 08908 L'Hospitalet de Llobregat, Barcelona, Spain., Bachanova V; University of Minnesota, Minneapolis, Minnesota., Maziarz RT; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Dreyling M; Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois., Jacobson C; Dana-Farber Cancer Institute, Boston, Massachusetts., Glass B; Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Casulo C; Department of Hematology/Oncology, University of Rochester, Rochester, New York., Oluwole OO; Vanderbilt University Medical Center, Nashville Tennessee., Montoto S; Department of Haemato-oncology St.Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Advani R; Department of Medicine, Stanford University, Stanford, California., Cohen J; Emory University, Atlanta, Georgia., Salles G; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Hamad N; Department of Haematology, St Vincent's Hospital Sydney, Australia. School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia. School of Medicine, Sydney, University of Notre Dame Australia, Sydney, New South Wales, Australia., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Kahl BS; Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri., Shadman M; Fred Hutchinson Cancer Center, Seattle, Washington., Kanate AS; HonorHealth Cancer Transplant Institute, Scottsdale, Arizona., Budde LE; City of Hope National Medical Center, Duarte, California., Kamdar M; University of Colorado Cancer Center, Aurora, Colorado., Flowers C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hamadani M; CIBMTR/Medical College of Wisconsin, Milwaukee, Wisconsin., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Jazyk: angličtina
Zdroj: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep; Vol. 30 (9), pp. 832-843. Date of Electronic Publication: 2024 Jul 06.
DOI: 10.1016/j.jtct.2024.06.025
Abstrakt: Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rates and long-term remissions, but definitive statement on the curative potential of CAR-T is currently not possible due to limited patient numbers and relatively short follow up. A consensus on the contemporary role, optimal timing, and sequencing of HCT (autologous or allogeneic) and cellular therapies in FL is needed. As a result, the American Society of Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines endorsed this effort to formulate consensus recommendations to address this unmet need. The RAND-modified Delphi method was used to generate 15 consensus statements/recommendations. These clinical practice recommendations will help guide clinicians managing patients with FL. Of note, the use of bispecific antibodies in R/R FL was not in the scope of this project.
(Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: